Fluxion Biosciences Awarded NCI Grant For Development Of Rare Cell Isolation Platform
Main Category: Cancer / OncologyArticle Date: 23 Jul 2009 - 22:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Fluxion Biosciences, a leading developer of microfluidic systems for cellular analysis in life science research, announced that it has received a $200K grant from the National Cancer Institute (NCI) for the development of a rare cell isolation platform for diagnostic and research applications. The Phase One Small Business Innovation Research Grant will enable Fluxion to further develop its innovative microfluidic platform. The endpoints of this research include enhanced methods for detecting circulating tumor cells that appear in very low concentrations in the early stages of cancer.
Circulating tumor cells (CTCs) are cells that detach from a primary tumor and circulate throughout the bloodstream. These cells are part of the metastasizing process that leads to the progression of the disease. It is widely believed that the detection of CTCs in the blood is an important factor in monitoring an individual's baseline condition and ongoing response to therapy. Despite the high value of this information, these tests are rarely performed due to the difficulty in tracking CTCs, which can appear in as little as one in one billion blood cells. This newly awarded grant is focused on the development of a microfluidic system that enhances the detection ability of CTCs as well as other rare cell types. The principal aims of this grant include the design of novel microfluidic systems for magnetic-bead based cell separations and the associated control instrumentation.
"We are excited to receive this NCI grant for this compelling application of our microfluidic technology," said Carolyn Conant, Ph.D., project leader for the grant. "The ability to detect and isolate rare cells can have a profound impact in the fields of oncology, immunology and neonatal care."
Source
Fluxion Biosciences
Visit our cancer / oncology section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/158588.php>
APA
http://www.medicalnewstoday.com/releases/158588.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




